Research Interests

• The breakthrough point in the innovation of targeted therapy in leukemia (i.e. the most common cancer among people under the age of 35) is to acquire the structural information of key oncogenic proteins. This in turn will help to advance the understanding of the pathogenic research and new drug development. Dr. Meng’s team has pioneered in the field of "structural biology of leukemia" (Zhang et al, BLOOD, 2022; Zhang et al, Cancer Communications, 2021; Li et al, Trends in Cancer, 2020; Li et al, Nature Communications, 2019; Wang et al, Nature communications, 2018; Dong et al, Leukemia, 2018).

• In recent years, Dr. Meng has published 33 papers in high-impact journals including Blood (2); Nat Commun (5), Leukemia (2), EMBO J (2), Trends in Cancer as a senior author, and has won many honors such as the Shanghai Medical Award（2）and the Chinese Medical Award as the first accomplisher. Meanwhile, one patent is being applied. Dr. Meng’s major research interests/efforts are: 1) how oncogenic fusion drives leukemogenesis in AML and ALL leukemias; 2) how mRNA vaccine could be used in cancer treatments.